Comparative Effects of Tadalafil and PRP on Cavernosal Inflammatory Markers in Vasculogenic ED: A Comparative Study

Cavernosal C-Reactive Protein and Fibrinogen Levels as Inflammatory Biomarkers before and after Intracavernosal Platelet Rich Plasma Injection versus oral Daily Tadalafil 5mg treatment in Patients with Vasculogenic Erectile Dysfunction: Comparative Study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

PACTR

Registry ID

PACTR202506917694681

Enrollment

Registered

2025-06-19

Start date

2023-03-15

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urological and Genital Diseases

Interventions

Tadalafil

none

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Male participants aged 19–64 years Diagnosed with vasculogenic erectile dysfunction Stable heterosexual relationship for at least 3 months No ED treatment in the previous 6 months Willing and able to provide written informed consent Regular sexual activity (at least once weekly)

Exclusion criteria

Exclusion criteria: Peyronie’s disease or significant penile deformity ED due to neurogenic, hormonal, or psychogenic causes Use of psychotropic drugs, antipsychotics, or antihypertensives affecting sexual function Active malignancy, autoimmune disease, or coagulopathy Abnormal hormonal profile (FSH, LH, or prolactin) Previous penile surgery or trauma Contraindications to PRP or tadalafil therapy

Design outcomes

Primary

Measure	Time frame
Change in cavernosal C-reactive protein (CRP) and fibrinogen levels	—

Secondary

Measure	Time frame
Secondary Outcome 1 Change in International Index of Erectile Function-5 (IIEF-5) score ;Secondary Outcome 1 Outcome Type: ? Secondary Outcome Outcome: Change in International Index of Erectile Function-5 (IIEF-5) score Time point(s) at which outcome measured: Baseline and 6 weeks post-treatment Change in penile duplex Doppler parameters (peak systolic velocity, end-diastolic velocity, resistive index)	—

Measure

Time frame

Secondary Outcome 1 Change in International Index of Erectile Function-5 (IIEF-5) score ;Secondary Outcome 1 Outcome Type: ? Secondary Outcome Outcome: Change in International Index of Erectile Function-5 (IIEF-5) score Time point(s) at which outcome measured: Baseline and 6 weeks post-treatment Change in penile duplex Doppler parameters (peak systolic velocity, end-diastolic velocity, resistive index)

—

Countries

Egypt

Contacts

Public ContactMohamed Hasan

Professor Al Azhar University

mohamed.saeed80@hotmail.com+20225103322

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026